S. 3131 118th Congress
ORPHAN Cures Act
Latest action, Oct 25, 2023: Read twice and referred to the Committee on Finance.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
3 cosponsors
Sponsored by John Barrasso (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
1 D · 2 R
- Democrat
- Republican
- Independent
Referred to: Senate: Finance Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
5 reports
5 reports
5 reports
RARE DISEASE COMPANY COALITION
THE KPM GROUP DC LLC
5 reports
5 reports
4 reports
4 reports
4 reports
4 reports
NOVARTIS, INC.
TODD STRATEGY GROUP
4 reports
4 reports
4 reports
TAKEDA PHARMACEUTICALS AMERICA, INC.
CROSSROADS STRATEGIES, LLC
4 reports
UCB, INC.
4 reports
All 25 of 36 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ASTRAZENECA PHARMACEUTICALS LP | 5 | $3.8M | Q4 2023 | Q3 2024 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 5 | $8.9M | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 5 | $6.9M | Q4 2023 | Q3 2024 | yes | |
| RARE DISEASE COMPANY COALITION | THE KPM GROUP DC LLC | 5 | $620K | Q4 2023 | Q3 2024 | yes |
| TRAVERE THERAPEUTICS | 5 | $635K | Q4 2023 | Q3 2024 | yes | |
| ACADIA PHARMACEUTICALS | 4 | $1.4M | Q1 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $6.7M | Q1 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | AVOQ, LLC | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| JAZZ PHARMACEUTICALS, INC. | 4 | $2.0M | Q1 2024 | Q3 2024 | yes | |
| LUNDBECK LLC | 4 | $550K | Q1 2024 | Q3 2024 | yes | |
| NOVARTIS, INC. | TODD STRATEGY GROUP | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| SANOFI US SERVICES INC | 4 | $5.5M | Q1 2024 | Q3 2024 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 4 | $2.9M | Q1 2024 | Q3 2024 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | CROSSROADS STRATEGIES, LLC | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| UCB, INC. | 4 | $1.1M | Q1 2024 | Q3 2024 | yes | |
| AARP | 3 | $15.6M | Q4 2024 | Q3 2024 | yes | |
| ALEXION PHARMACEUTICALS, INC. | TODD STRATEGY GROUP | 3 | $240K | Q4 2024 | Q3 2024 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | TODD STRATEGY GROUP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| GILEAD SCIENCES, INC. | THE MCMANUS GROUP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| PATIENTS RISING NOW | YC CONSULTING, LLC | 3 | $220K | Q4 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | THE MCMANUS GROUP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOW | TIDAL BASIN ADVISORS, INC. | 3 | $30K | Q4 2024 | Q3 2024 | yes |
| YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOW | LONG STRATEGIES, INC. | 3 | $30K | Q4 2024 | Q3 2024 | yes |
| ALEXION PHARMACEUTICALS, INC. | FORBES-TATE | 2 | $100K | Q4 2024 | Q3 2024 | yes |
| ASTRAZENECA | TIBER CREEK GROUP | 2 | $120K | Q4 2024 | Q3 2024 | yes |